New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
04:55 EDTSTAA, STAA, STAA, VTL, VTL, VTL, ANAC, ANAC, ANAC, PTCT, PTCT, PTCT, SGMO, SGMO, SGMO, RNA, RNA, RNA, BLUE, BLUE, BLUE, BIND, BIND, BIND, FCSC, FCSC, FCSC, CRDC, CRDC, CRDC, DRTX, DRTX, DRTXWedbush to hold a conference
Life Sciences Management Conference to be held in New York on August 12-13.
News For DRTX;CRDC;FCSC;BIND;BLUE;RNA;SGMO;PTCT;ANAC;VTL;STAA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 23, 2014
09:12 EDTCRDCCardica shareholder Broadfin seeks election of three directors to the Board
Cardica shareholder Broadfin Capital, beneficial owner of approximately 17.3% of the shares of Cardica, filed preliminary proxy materials with the SEC to seek the election of its three independent candidates to Cardica's Board of Directors at the upcoming Annual Shareholder Meeting on December 11. In the proxy materials, Broadfin states that "the strategic, operational and financial failures of the current Board and management of Cardica" are resulting in "the continued material destruction of shareholder value." "The Board's recent reactive addition of two new directors does not go far enough in building the strong, diverse, experienced and independent group of directors that are best positioned to lead our company."
October 22, 2014
17:33 EDTCRDCCardica issues statement regarding Broadfin board nominations
Subscribe for More Information
16:12 EDTSGMOSangamo backs FY14 revenue view $45M-$50M, consensus $47.57M
Subscribe for More Information
16:06 EDTSGMOSangamo reports Q3 EPS (11c), consensus (14c)
Subscribe for More Information
October 21, 2014
07:06 EDTBLUEFierce Biotech to hold a breakfast meeting
Subscribe for More Information
October 20, 2014
07:16 EDTSTAAAmerican Academy of Ophthalmology to hold annual meeting
AAO Annual Meeting 2014 is being held in Chicago on October 18-21.
06:50 EDTRNAProsensa upgraded to Overweight from Underweight at JPMorgan
JPMorgan upgraded Prosensa two notches to Overweight citing a favorable risk/reward around the potential approval of Drisapersen for Duchenne muscular dystrophy. The firm believes regulatory risk for the drug has been significantly reduced in both the U.S. and Europe. JPMorgan raised its price target for shares to $18 from $4.40.
October 15, 2014
10:02 EDTDRTXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:54 EDTDRTXDurata Therapeutics downgraded to Neutral from Buy at Roth Capital
Subscribe for More Information
October 14, 2014
11:23 EDTBINDBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
10:01 EDTDRTXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:10 EDTDRTXDurata Therapeutics downgraded to Neutral from Outperform at Credit Suisse
Durata Therapeutics (DRTX ) is being acquired by Actavis (ACT) for $23 per share and $5 in contingent value rights and Credit Suisse does not believe a higher bid will emerge.
07:04 EDTBLUEbluebird bio says first patient with sicle cell disease undergoes infusion
Subscribe for More Information
October 10, 2014
13:45 EDTDRTXDurata Therapeutics announces new data for dalbavancin
Subscribe for More Information
10:12 EDTRNAProsensa begins NDA submission to FDA for drisapersen
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use